Related Experiment Video

Updated: May 15, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Antidepressants do not improve event-free survival in patients with heart failure when depressive symptoms remain

Misook L Chung1, Rebecca L Dekker, Terry A Lennie

  • 1RICH Heart Program, University of Kentucky College of Nursing, Lexington, KY 40536-0232, USA. misook.chung@uky.edu

Heart & Lung : the Journal of Critical Care
|January 12, 2013
PubMed

Insights

Depressive symptoms, not antidepressant use, impact event-free survival in heart failure patients. Untreated depression significantly increases risks of death and hospitalization, highlighting the need for ongoing patient assessment.

Area of Science:

  • Cardiology
  • Psychiatry
  • Clinical Research

Background:

  • Heart failure (HF) is a complex condition often co-occurring with depressive symptoms.
  • The interplay between depressive symptoms, antidepressant use, and HF outcomes requires further investigation.

Purpose of the Study:

  • To compare event-free survival in heart failure patients stratified by depressive symptoms and antidepressant use.
  • To determine the predictive value of depressive symptoms and antidepressant therapy on HF outcomes.

Main Methods:

  • Secondary analysis of data from 209 HF outpatients in a multicenter registry.
  • Assessment of depressive symptoms using the Patient Health Questionnaire-9.
  • 1-year follow-up for cardiac rehospitalization and death, controlling for clinical covariates.

Main Results:

  • Depressive symptoms, not antidepressant therapy, significantly predicted event-free survival (HR=2.4, p=0.009).
  • Depressed patients without antidepressants faced a 4.1-fold higher risk of death/hospitalization compared to non-depressed patients on antidepressants (p=0.022).

Conclusions:

  • Antidepressant use did not predict event-free survival in patients with ongoing depressive symptoms.
  • Continuous monitoring of HF patients on antidepressants is crucial to ensure treatment efficacy and improve outcomes.
Abstract

More Related Videos

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder04:33

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Published on: April 26, 2024

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...